###### Strengths and limitations of the study

-   The first study to characterise the haematological profile of individuals with reduced kidney function in a population-based setting in Africa, even more specific, individuals of mixed-ancestry.

-   We studied a community with a high burden of obesity, hypertension and diabetes, reflective of the current burden in Africa.

-   This study was conducted in only one geographical area which may not adequately reflect all the mixed ancestry population groups in Sub-Saharan Africa.

-   Our study was based on a single serum creatinine measure to determine chronic kidney disease (CKD) and did not include estimates of albuminuria. Albuminuria, which are required for clinical and aetiological diagnosis of CKD, as this information is important particularly in the interpretation of estimated glomerular filtration rate (eGFR) greater that 60 mL/min/1.73 m^2^ where inaccuracies of the eGFR equations are greatest.

Background {#s1}
==========

Chronic kidney disease (CKD) is a major global public health problem,[@R1] estimated to affect more than 10% of the general adult population and up to 50% of some high-risk subpopulations, such as the elderly,[@R2] those with non-communicable diseases (NCDs), including type 2 diabetes mellitus (T2D) and hypertension, and communicable diseases (CDs), including HIV/AIDS.[@R3] Africa is currently experiencing the double burden of NCDs and CDs which are all driving the increasing burden of CKD on the continent.[@R5] However, the exact burden of CKD in Africa has yet to be fully elucidated,[@R6] in part due to the absence of appropriate estimates for predicting reduced kidney function in individuals from African ancestry.[@R9]

CKD encompasses a wide range of physiological processes altered by the progressive decline in glomerular filtration rate (GFR).[@R11] Haematological parameters, particularly red blood cell (RBC) indices, are most commonly affected,[@R13] giving rise to anaemia. Anaemia is the most common, consistent and severe of the various haematological abnormalities, and has been shown to be a very common condition in black Africans.[@R14] Although anaemia may be found at any stage of CKD, the severity of anaemia increases with CKD progression,[@R15] resultantly affecting nearly all patients with end-stage renal disease (CKD stage 5).[@R13] The predominant cause of anaemia in CKD is failure of the kidneys to produce enough endogenous erythropoietin, which accompanies the fall in GFR.[@R16] Untreated, prolonged anaemia is strongly predictive of all-cause and cardiovascular mortality, as well as reduced quality of life and increased morbidity in patients with CKD.[@R13] Untreated anaemia can also accelerate the decline in renal function by causing renal haemodynamic alterations and tissue hypoxia.[@R15] Other potentially affected haematological parameters in CKD, of which the association with CKD is not yet fully characterised, include total and differential white blood cell (WBC) counts. Persistent, low-grade inflammation is an essential part of the aetiology of CKD and has been recognised as such since the late 1990s, when it was linked to cardiovascular disease and mortality.[@R19] Recently, the ratio of neutrophil-to-lymphocyte count (N/L) has been proposed as a novel measure of inflammation in distinct populations and has been shown to have prognostic value[@R20]; particularly for mortality risk in patients with myocardial infarction and heart failure.[@R21] However, studies on the relationship of N/L ratio with reduced estimated GFR (eGFR) are limited.[@R23] Thus, despite recent advances in the aetiology governing the development and progression of CKD, population-based data on the haematological profile of people with CKD in Africa are scanty.

We therefore aimed to characterise the haematological profile of screen-detected CKD participants in a community-based sample, and to correlate the complete blood count measures with two commonly advocated kidney function estimators of CKD in urban South Africans of mixed-ancestry.

Methods {#s2}
=======

Study setting and population {#s2a}
----------------------------

The current study used data from the ongoing Cape Town Vascular and Metabolic Health study, an extension of the Cape Town Bellville-South study, which has been described in detail previously.[@R24] Bellville-South, with a population of approximately 29 301, is a township formed in the late 1950s, located in the metropolitan city of Cape Town, South Africa. The population consists predominantly of individuals of mixed-ancestry (coloured) (76%), followed by black Africans (18.5%), with only 1.5% of the population being of Caucasian and Asian ancestry. The data collection for the current analysis took place between February 2015 and November 2016 during a community-based survey involving only mixed-ancestry South Africans.

### Participant involvement {#s2a1}

The participants were not involved in the design or recruitment process of this study. However, permission to conduct the study was obtained from relevant authorities including the city and community authorities.

Questionnaires and physical examination {#s2b}
---------------------------------------

All interviews and physical examinations took place at a research clinic on the campus of Cape Peninsula University of Technology, located within the study suburb. All consenting participants received a standardised interview, explained in great detail elsewhere.[@R25] Physical examination involved blood pressure (BP) determination, measured according to the WHO guidelines,[@R26] using a semiautomatic digital BP monitor (Omron M6 comfort-preformed cuff BP Monitor), placed on the right arm in sitting position and at rest for at least 10 min. Three measures were taken of which the average of the lowest two was used in all analyses. Body weight (to the nearest 0.1 kg) was measured with the participant in light clothing and without shoes, using an Omron body fat meter HBF-511 digital bathroom scale which was calibrated and standardised using a weight of known mass. Height (to the nearest centimetre) was measured with a stadiometer, with subjects standing on a flat surface. Body mass index (BMI) was calculated as body weight per body height squared (kg/m^2^). Waist circumference (WC) was measured with a non-elastic tape measure at the level of the narrowest part of the torso, as seen from the anterior view. Anthropometric measurements were performed three times and the average used for analysis.

Biochemical analysis and calculations {#s2c}
-------------------------------------

All biochemical analyses took place at an ISO 15189 accredited Pathology practice (Path-Care, Reference Laboratory, Cape Town, South Africa). Blood samples were collected from all participants after an overnight fast, and 2 hours after a 75 g oral glucose tolerance test (OGTT) following the WHO recommendations.[@R27] Plasma glucose levels and haemoglobin A1c (HbA1c) were measured by enzymatic hexokinase method (Beckman AU, Beckman Coulter, South Africa) and high performance liquid chromatography (Biorad Variant Turbo, BioRad, South Africa), respectively. Insulin was determined by a paramagnetic particle chemiluminescence assay (Beckman DXI, Beckman Coulter, South Africa). Triglycerides (TG), total cholesterol (TC), and high-density lipoproteins (HDL-C) were analysed using the Roche Modular auto analyser and enzymatic colorimetric assays, and low-density lipoproteins (LDL-C) were calculated using the Friedewald formula.[@R28] The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated according to the formula: HOMA-IR = \[fasting insulin concentration (mIU/l)×fasting plasma glucose (mmol/l)/22.5. Serum concentration of high sensitivity C-reactive protein (hsCRP) (Immun Diagnostik AG, Bensheim, Germany) was analysed using commercially available ELISA kits according to the manufacturer's protocols. Serum creatinine was measured by the modified Jaffe-Kinetic method (Beckman AU, Beckman Coulter, South Africa). Creatinine assays at our Partner pathology service are standardised to the internationally accepted reference method (isotope dilution mass spectrophotometry) since 2009 and eGFR estimators applicable to standardised creatinine values were used. Kidney function was assessed using serum creatinine-based eGFR, namely, the 4-variable Modification of Diet in Renal Disease (MDRD) equation[@R29] and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation[@R30]. The African-American ethnicity correction factor was omitted from the eGFR calculation, as the South African Renal Society CKD guidelines promote the exclusion of the correction factor, except in the case of black Africans. Full blood counts, including total RBC, total WBC, lymphocytes count and percentage, monocyte count and percentage, neutrophil count and percentage, basophil count and percentage, eosinophil count and percentage, haemoglobin, haematocrit, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), MCH concentration (MCHC), red cell distribution width (RDW) and platelets were measured on a Coulter LH 750 haematology analyser (Beckman Coulter, South Africa).

Classification of renal function and comorbidities {#s2d}
--------------------------------------------------

Staging of kidney function was based on the National Kidney Foundation Disease Outcomes Quality Initiative classification.[@R31] An eGFR \<60 mL/min/1.73 m^2^ was used to define CKD (or CKD stage 3--5). Anaemia was defined using the National Kidney Foundation Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines (haemoglobin level \<13.5 g/dL for men and \<12 g/dL for women)[@R32] and further classified into microcytic, normocytic and macrocytic based on the MCV. Microcytic anaemia was defined as an MCV of \<80 fL, normocytic as 100--80 fL and macrocytic as \>100 fL.[@R33] Hypertension was based on either a history of diagnosed hypertension (receiving medications for hypertension) or screen-detected hypertension. The latter being classified if they had a systolic BP (SBP) ≥140 mm Hg and/or diastolic BP ≥90 mm Hg.[@R34] Diabetes status was based on a history of diagnosed diabetes or screen-detected diabetes. OGTT glucose values were used to classify the glucose tolerance status of participants as recommended by WHO[@R35] as: (1) normal glucose tolerance (fasting plasma glucose (FPG) \<6.1 mmol/L and 2-hour glucose \<7.8 mmol/L); (2) pre-diabetes including impaired fasting glycaemia (IFG, 6.1≤FPG\<7.0 mmol/L), impaired glucose tolerance (IGT, 7.8\<2-hour glucose \<11.1 mmol/L) and the combination of both; and (3) diabetes (FPG ≥7.0 mmol/L and/or 2-hour glucose ≥11.1 mmol/L). BMI ≥25 kg/m^2^ and BMI ≥30 kg/m^2^ were classified as overweight and obese, respectively.

Statistical analysis {#s2e}
--------------------

All statistical analyses were performed using STATA V.13 (Statcorp), and statistical significance was based on a p value \<0.05. General characteristics of the participants are summarised as count and percentage for qualitative variables and median and 25th--75th percentiles for quantitative variables. Group comparisons used χ^2^ test for qualitative variables, and Wilcoxon rank-sum test for quantitative variables, respectively. Multiple linear regression models were used to assess the independent association between eGFR and haematological indices, while adjusting for age and gender.

Results {#s3}
=======

Participant characteristics {#s3a}
---------------------------

The initial study sample comprised 1647 participants. Of those, 83 were excluded due to missing data on serum creatinine or any of the variables required to estimate kidney function, including age and gender. The general characteristics and the haematological profile of the study population are summarised in [tables 1 and 2](#T1 T2){ref-type="table"}, respectively. The final sample included 1564 participants, of which 24.9% were male, with a group median age of 50 years. The crude prevalence of CKD was 6% and 3%, based on the MDRD and CKD-EPI equations, respectively. Of those participants with MDRD-diagnosed CKD, 80.7%, 14.8% and 4.5% where in stages 3, 4 and 5, respectively. Similarly, of those diagnosed by means of the CKD-EPI equation, 68.9%, 24.4% and 6.7% where in stages 3, 4 and 5, respectively. MDRD-diagnosed CKD participants had higher creatinine levels (111.5 vs 59 µmol/L; p\<0.0001) and lower eGFR (48.2 vs 104 mL/min/1.73 m^2^; p\<0.0001), were on average older (68 vs 49 years; p\<0.0001), with a higher WC (97.7 vs 91.2 cm; p=0.0001), BMI (30.3 vs 28.3 kg/m^2^; p=0.0096), and SBP (142 vs 125 mm Hg; p\<0.0001), compared with participants with normal kidney function. Furthermore, MDRD-diagnosed CKD participants had higher fasting and 2-hour blood glucose (5.3 vs 5.0 mmol/L; p\<0.0001 and 7.2 vs 6.0 mmol/L; p\<0.0001, respectively), HbA1c levels (6.2 vs 5.7%; p\<0.0001), fasting and 2-hour insulin levels (8.4 vs 6.7 IU/L; p=0.0089 and 62.0 vs 37.5 IU/L; p=0.0002, respectively), higher HOMA-IR index (2.1 vs 1.6; p=0.0004), hsCRP (4.7 vs 4.0 µg/mL; p=0.0492), TG (1.6 vs 1.2 mmol/L; p\<0.0001) and TC (5.4 vs 5.1 mmol/L; p=0.024); with similar LDL-C (3.2 vs 3.1 mmol/L; p=0.0668) and HDL-C levels (1.3 vs 1.3 mmol/L; p=0.7106) compared with those without CKD. When subdividing the groups based on CKD diagnosed by the CKD-EPI equation, similar differences were observed, with the exception of BMI, hsCRP and TC which showed no difference between the groups (28.3 vs 28.4 kg/m^2^; p=0.384, 4.8 vs 4.0 µg/mL; p=0.4268, 5.3 vs 5.1 mmol/L; p=0.2226, respectively). Participants with reduced kidney function, both MDRD and CKD-EPI diagnosed, had a similar prevalence of overweight and obesity, however had a higher prevalence of hypertension and T2D, despite similar prevalence of pre-diabetes (IFG and IGT) between the two groups.

###### 

Clinical characteristics of the study population overall and by CKD (MDRD and CKD-EPI) status

  Variables                              Total (n=1564)        MDRD                  CKD-EPI                                                                       
  -------------------------------------- --------------------- --------------------- --------------------- ---------- ---------------------- --------------------- ----------
  Age (years)                            50 (37--61)           49 (36--59)           68 (62--74)           \<0.0001   50 (36--60)            69 (63--77)           \<0.0001
  Gender (n, % male)                     389 (24.9)            372 (25.3)            17 (18.1)             0.215      373 (24.6)             16 (34.0)             0.093
  Anthropometry                                                                                                                                                    
   Weight (kg)                           72.0 (59.2--85.5)     71.9 (59.0--85.5)     74.0 (64.6--85.8)     0.2058     72.0 (59.2--85.5)      73.5 (64.1--85.7)     0.6903
   WC (cm)                               91.8 (78.5--103.5)    91.2 (77.8--103.0)    97.7 (89.0--105.8)    0.0001     91.5 (78.1--103.5)     96.0 (87.8--106.5)    0.0225
   HC (cm)                               102.8 (92.5--113.5)   102.5 (92.1--113.5)   104.3 (96.5--114.2)   0.1138     102.8 (92.5--113.8)    101.5 (95.8--111.5)   0.9439
   BMI (kg/m^2^)                         28.4 (22.9--34.2)     28.3 (22.7--34.1)     30.3 (26.1--35.1)     0.0096     28.4 (22.9--34.2)      28.3 (24.7--34.4)     0.3836
  Biochemical analysis                                                                                                                                             
   Fasting blood glucose (mmol/L)        5.0 (4.6--5.7)        5.0 (4.6--5.6)        5.3 (5.0--6.9)        \<0.0001   5.0 (4.6--5.6)         5.3 (5.0--7.7)        0.0014
   2Hour glucose (mmol/L)                6.0 (4.9--7.6)        6.0 (4.8--7.5)        7.2 (5.8--9.2)        \<0.0001   6.0 (4.8--7.5)         7.5 (5.7--9.2)        0.0034
   HbA1c (%)                             5.8 (5.4--6.3)        5.7 (5.4--6.2)        6.2 (5.9--7.1)        \<0.0001   5.8 (5.4--6.2)         6.4 (5.9--7.3)        \<0.0001
   Fasting insulin (IU/L)                6.7 (4.3--11.1)       6.7 (4.2--10.9)       8.4 (5.3--12.4)       0.0089     6.7 (4.2--10.9)        9.0 (5.3--12.4)       0.0323
   2-Hour insulin (IU/L)                 38 (20.6--71.8)       37.5 (19.8--69.8)     62.0 (30.3--105.6)    0.0002     37.8 (20.3--70.5)      63.5 (32.6--105.2)    0.0072
   HOMA-IR (MU)                          1.6 (0.9--2.9)        1.6 (0.9--2.8)        2.1 (1.2--3.9)        0.0004     1.6 (0.9--2.8)         2.4 (1.3--3.8)        0.0026
   hsCRP (µg/mL)                         4.0 (1.6--8.8)        4.0 (1.6--8.8)        4.7 (2.7--9.3)        0.0492     4.0 (1.6--8.8)         4.8 (2.4--7.5)        0.4268
   TG (mmol/L)                           1.2 (0.9--1.7)        1.2 (0.9--1.7)        1.6 (1.2--2.3)        \<0.0001   1.2 (0.9--1.7)         1.8 (1.1--2.4)        0.0001
   TC (mmol/L)                           5.1 (4.4--5.9)        5.1 (4.3--5.9)        5.4 (4.8--6.4)        0.0024     5.1 (4.4--5.9)         5.3 (4.4--6.0)        0.2226
   LDL-C (mmol/L)                        3.1 (2.5--3.8)        3.1 (2.5--3.8)        3.2 (2.7--4.3)        0.0668     3.1 (2.5--3.8)         3.1 (2.5--3.9)        0.9444
   HDL-C (mmol/L)                        1.3 (1.1--1.5)        1.3 (1.1--1.5)        1.3 (1.1--1.5)        0.7106     1.3 (1.1--1.5)         1.3 (1.1--1.4)        0.5132
   Creatinine (µmol/L)                   60 (52--70)           59 (51--68)           111.5 (89.0--140.5)   \<0.0001   59 (51--69)            140 (124--209)        \<0.0001
   eGFR (mL/min/1.73 m^2^)               \-                    104.0 (88.0--121.0)   48.2 (33.7--55.4)     \<0.0001   113.9 (101.4--126.5)   44.7 (26.4--49.6)     \<0.0001
  Blood pressure measures                                                                                                                                          
   Mean SBP (mm Hg)                      125 (111--141)        125 (110--140)        142 (121--162)        \<0.0001   125 (111--140)         150 (128--181)        \<0.0001
   Mean DBP (mm Hg)                      81 (72--90)           81 (72--90)           81 (74--95)           0.2114     81 (72--90)            85 (73--95)           0.2185
   Pulse pressure (BPM)                  70 (62--79)           70 (62--79)           70 (60--81)           0.9932     70 (62--79)            73 (62--82)           0.3861
  Comorbidities                                                                                                                                                    
   Overweight (BMI ≥25 kg/m^2^; n (%))   361 (23.2)            335 (22.9)            26 (29.5)             0.139      348 (23.1)             13 (28.9)             0.348
   Obese (BMI ≥30 kg/m^2^; n (%))        662 (42.6)            617 (42.1)            45 (51.1)             0.085      642 (42.5)             20 (44.4)             0.771
   Pre-diabetes, n (%)                   238 (15.2)            226 (15.4)            12 (12.8)             0.671      233 (15.4)             5 (10.6)              0.436
   T2D, n (%)                            297 (19.0)            259 (17.6)            38 (40.4)             \<0.0001   272 (17.9)             25 (53.2)             \<0.0001
   Hypertension, n (%)                   567 (36.3)            517 (35.2)            50 (53.2)             \<0.0001   537 (35.4)             30 (63.3)             \<0.0001

Data is presented as median (25th-75^th^ percentiles) and percentages.

BMI, body mass index; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, Glycated haemoglobin; HC, hip circumference; HDL-C, high-density lipoproteins; HOMA-IR, Homeostatic model assessment-insulin resistance; hsCRP, high sensitivity C-reactive protein; IFG/IGT, impaired fasting glucose and impaired glucose tolerance; LDL-C, low-density lipoproteins; MU, mass units; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; T2D, type 2 diabetes mellitus; WC, waist circumference.

###### 

Haematological profile of study population overall and by CKD (MDRD and CKD-EPI) status

  Variables                      Total (n=1564)      MDRD                CKD-EPI                                                                
  ------------------------------ ------------------- ------------------- ------------------- ---------- ------------------- ------------------- ----------
  RBC (x10^12^/L)                4.7 (4.3--5.0)      4.7 (4.4--5.0)      4.3 (3.9--4.7)      \<0.0001   4.7 (4.4--5.0)      4.2 (3.8--4.7)      \<0.0001
  WBC (x10^9^/L)                 7.5 (6.2--9.1)      7.4 (6.2--9.1)      7.7 (6.5--9.2)      0.5704     7.4 (6.2--9.1)      7.9 (6.3--9.3)      0.5458
   N/L (ratio)                   2.0 (1.5--2.6)      1.9 (1.5--2.5)      2.5 (1.7--3.5)      \<0.0001   1.9 (1.5--2.5)      2.7 (2.0--3.7)      \<0.0001
   Lymphocyte count (x10^9^/L)   2.2 (1.8--2.80)     2.2 (1.8--2.8)      1.9 (1.4--2.5)      0.0001     2.2 (1.8--2.8)      1.8 (1.4--2.4)      \<0.0001
   Monocyte count (x10^9^/L)     0.5 (0.4--0.6)      0.5 (0.4--0.6)      0.4 (0.4--0.6)      0.1389     0.5 (0.4--0.6)      0.4 (0.4--0.6)      0.9446
   Neutrophil count (x10^9^/L)   4.5 (3.4--5.7)      4.5 (3.3--5.6)      5.0 (3.7--5.9)      0.0255     4.5 (3.4--5.6)      5.1 (4.3--6.1)      0.0297
   Basophil count (x10^9^/L)     0.1 (0.1--0.2)      0.0 (0.0--0.0)      0.0 (0.0--0.1)      0.283      0.0 (0.0--0.0)      0.0 (0.0--0.1)      0.1366
   Eosinophil count (x10^9^/L)   0.2 (0.1--0.3)      0.2 (0.1--0.3)      0.2 (0.1--0.3)      0.1579     0.2 (0.1--0.3)      0.2 (0.1--0.3)      0.1223
  Platelet count (x10^9^/L)      271 (227--322)      271 (228--322)      277 (214--324)      0.9417     271 (228--322)      266 (197--313)      0.2211
  Haematocrit (volume %)         41 (39--44)         41 (39--44)         38 (35--41)         \<0.0001   41 (39--44)         37 (34--41)         \<0.0001
  MCV (fl/cell)                  89 (85--93)         89 (85--93)         89 (86--92)         0.8150     89 (85--93)         89 (86--91)         0.4748
  MCH (pg/cell)                  29 (28--31)         29 (28--31)         29 (28--30)         0.1399     29 (28--31)         29 (28--30)         0.057
  MCHC (g/dL)                    33 (32--33)         33 (32--33)         33 (32--33)         0.1471     33 (32--33)         32 (32--33)         0.1156
  RDW (%)                        14.2 (13.5--15.0)   14.1 (13.4--15.0)   14.5 (13.7--15.6)   0.0601     14.1 (13.4--15.0)   14.3 (13.8--15.5)   0.0673
  Hb (g/dL)                      13.5 (12.6--14.4)   13.5 (12.7--14.5)   12.2 (11.2--13.3)   \<0.0001   13.5 (12.6--14.4)   11.9 (11.1--13.2)   \<0.0001
  Anaemia, n (%)                 289 (18.48)         249 (16.9)          40 (45.5)           \<0.0001   263 (17.3)          26 (57.8)           \<0.0001
   Microcytic                    83 (28.7)           83 (33.3)           0 (0.0)             --         83 (31.6)           0 (0.0)             --
   Normocytic                    180 (62.3)          141 (56.6)          39 (97.5)           --         155 (58.9)          25 (96.2)           --
   Macrocytic                    26 (9.0)            25 (10.0)           1 (2.5)             --         25 (9.5)            1 (3.8)             --

Data are presented as median (25th-75th percentiles) and percentages.

CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Hb, haemoglobin; MCH, mean corpuscular Hb; MCHC, MCH concentration; MCV, mean corpuscular volume; MDRD, Modification of Diet in Renal Disease; N/L ratio, lymphocyte to neutrophil ratio; RBC, red blood cells; RDW, red cell distribution width; WBC, white blood cells.

The RBC indices, including RBC count, haematocrit and haemoglobin levels were consistently lower in CKD participants compared with the group with normal kidney function (all p\<0.0001), irrespective of the eGFR equation used. Conversely, the morphology of the RBCs were not different, as similar values for MCV, MCH, MCHC and RDW were observed between CKD participants and the participants with normal kidney function. Despite not showing any significant difference in total WBC count between the two groups, the number of lymphocytes were lower and neutrophil count and the ratio of lymphocytes to neutrophil higher in the CKD group compared with those individuals with normal kidney function; with the remaining WBC indices similar in the two groups. The platelet count was similar in both groups. Furthermore, based on the K/DOQI guidelines, 45.5% (MDRD) and 57.8% (CKD-EPI) of the CKD participants had anaemia, with the majority of cases being normocytic. Moreover, the prevalence of anaemia increased with increasing severity of CKD, from 37.2% at stage 3% to 82.4% at stage 4--5.

Association between the different haematological indices and eGFR {#s3b}
-----------------------------------------------------------------

The age and gender-adjusted associations between the different haematological indices and eGFR, estimated by means of the MDRD and CKD-EPI equations, are presented in [table 3](#T3){ref-type="table"}. Based on the CKD-EPI, however not the MDRD equation, eGFR was positively associated with all the RBC indices, including total RBC count, haemoglobin and haematocrit levels. eGFR was not associated with total WBC count, however a lower lymphocyte count was associated with a lower eGFR, and N/L ratio was inversely associated with eGFR. Furthermore, male gender was significantly associated with all haematological measures, except basophil count and eosinophil count, and age was inversely associated with all RBC indices, lymphocytes, neutrophils, platelet count, MCHC and positively associated with RDW.

###### 

Linear regression coefficients, adjusted for age, gender (model 1) and eGFR (MDRD and CKD-EPI derived) (models 2) for the prediction of haematological-derived measures

  Model 1                       Model 2.1   Model 2.2                                                                                                                                          
  ----------------------------- ----------- --------------- ---------- --------- ------------------ ---------- ------ ------ ------------- ---------- ------ ------ --------------- ---------- ------
  RBC (x10^12^/L)               −2.8        −4.5 to −1.2    0.001      327.4     269.6 to 385.3     \<0.0001   0.08   0.3    −0.7 to 1.3   0.541      0.08   3.2    1.5 to 5.0      \<0.0001   0.09
  Haematocrit (%)               −0.2        −0.3 to −0.0    0.018      40.2      35.3 to 45.1       \<0.0001   0.15   0.0    −0.1 to 0.1   0.709      0.15   0.3    0.1 to 0.4      \<0.0001   0.16
  Hb (g/L)                      −0.1        −0.1 to −0.0    0.002      14.2      12.5 to 15.9       \<0.0001   0.16   0.0    −0.0 to 0.0   0.907      0.16   0.1    0.0 to 0.1      \<0.0001   0.16
  WBC (x10^9^/L)                −15.1       −22.3 to −7.8   \<0.0001   −431.9    −690.8 to −173.0   0.001      0.01   −0.5   −4.8 to 3.9   0.834      0.01   −1.7   −9.7 to 6.3     0.678      0.01
  N/L (%)                       −0.1        −3.8 to 3.5     0.941      136.2     5.6 to 266.7       0.041      0.00   −0.1   −0.4 to 0.1   0.214      0.00   −6.3   −10.3 to −2.3   0.002      0.01
  Lymphocyte count (x10^6^/L)   −2.9        −5.2 to −0.5    0.017      −257.10   −341.0 to −173.2   \<0.0001   0.02   0.7    −0.8 to 2.1   0.364      0.02   3.0    0.4 to 5.6      0.022      0.03
  Monocyte count (x10^6^/L)     −0.8        −1.4 to −0.2    0.005      91.6      71.2 to 112.0      \<0.0001   0.05   0.3    −0.1 to 0.6   0.114      0.05   0.5    −0.1 to 1.1     0.122      0.05
  Neutrophil count (x10^6^/L)   −10.9       −16.8 to −5.1   \<0.0001   −291.8    −500 to −82.8      0.006      0.01   −1.1   −4.6 to 2.4   0.542      0.01   −4.7   −11.1 to 1.7    0.150      0.01
  Basophil count (x10^6^/L)     1.6         −8.4 to 11.5    0.759      −187.9    −541.9 to 166.1    0.298      0.00   0.7    −5.3 to 6.6   0.822      0.00   −8.3   −19.2 to 2.6    0.136      0.00
  Eosinophil count (x10^6^/L)   −0.5        −1.1 to 0.0     0.067      15.9      −4.9 to 36.7       0.135      0.00   −0.4   −0.7 to 0.0   0.071      0.00   −0.6   −1.2 to 0.1     0.074      0.00
  Platelet count (x10^9^/L)     −0.4        −0.6 to −0.1    0.003      −33.0     −42.0 to −24.0     \<0.0001   0.03   0.1    −0.0 to 0.3   0.088      0.04   0.1    −0.0 to 0.3     0.088      0.04
  MCV (fL/100 cell)             1.4         −1.0 to 3.7     0.255      232.2     148.1 to 316.2     \<0.0001   0.02   −0.2   −1.6 to 1.2   0.761      0.02   0.1    −2.5 to 2.7     0.946      0.02
  MCH (pg/100 cell)             −0.2        −1.1 to 0.7     0.698      95.3      63.3 to 127.4      \<0.0001   0.02   −0.1   −0.7 to 0.4   0.646      0.02   0.1    −0.9 to 1.1     0.881      0.02
  MCHC (g/L)                    −0.1        −0.01 to −0.0   \<0.0001   2.3       0.9 to 3.8         0.002      0.02   −0.0   −0.0 to 0.0   0.227      0.02   −0.0   −0.1 to 0.0     0.664      0.01
  RDW (%)                       0.1         0.0 to 0.1      0.004      −1.9      −3.7 to −0.0       0.05       0.01   0.1    0.0 to 0.1    \<0.0001   0.02   0.1    0.0 to 0.1      0.025      0.01

Data presented as β-coefficient, 95% confidence interval CI and adjusted-R2.

Analyses are adjusted for age and gender.

Model 1 = age + gender; Model 2.1 = age + gender + eGFR (MDRD); Model 2.2 = age + gender + eGFR (CKD-EPI).

CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; Hb, haemoglobin; MCH, mean corpuscular Hb; MCHC, MCH concentration; MCV, mean corpuscular volume; MDRD, Modification of Diet in Renal Disease; N/L ratio, lymphocyte to neutrophil ratio; RBC, red blood cells; RDW, red cell distribution width; WBC, white blood cells.

Discussion {#s4}
==========

In this community-based sample of mixed-ancestry South Africans, we have shown that the haematological profile of individuals with reduced eGFR (\<60 mL/min/1.73 m^2^) are substantially impaired compared with those with normal kidney function, giving rise to the high prevalence of anaemia in this screen-detected CKD population. Furthermore, despite eGFR being positively associated with RBC indices, indicative of the severity of kidney function impairment, the disease state had no effect on the morphology of the RBC. Lastly, we confirmed that a chronic proinflammatory state exists in participants with CKD.

This study, which is in accordance with other studies in Africa and other low-income and middle-income countries,[@R36] has shown that CKD is associated with significant impairment in RBC indices. Indeed, we have shown that total RBC count, haemoglobin concentration and percentage haematocrit were substantially reduced in participants with eGFR below 60 mL/min/1.73 m^2^, compared with those with normal kidney function, independent of age and gender. Since erythropoietin is produced mainly by the proximal tubule of the nephron, kidney function decline will result in a decline in erythropoietin production and as a consequence result in decreased haemoglobin synthesis, leading to a fall in total RBC count.[@R17] This significant reduction in RBC, inevitably gives rise to anaemia.[@R14] Indeed, our study and numerous other studies have shown that the severity of anaemia increases with disease progression; with most of these studies showing anaemia at least twice as prevalent in participants with CKD, compared with the general adult population.[@R37] Furthermore, we found that 17% of the sample population with normal kidney function had haemoglobin levels \<13.5 g/dL and \<12 g/dL for men and women, respectively. However, this is not uncommon in Africa as previous studies have found that Africa has a high prevalence of anaemia caused by iron deficiency. In South Africa in particular, the South African National Health and Nutrition Examination Survey[@R43] showed that 22% and 12.2% of adult females and males have anaemia.

The activation of the immune system, caused by inflammation, increases WBC counts[@R23]; emphasising the potential of WBC indices as a surrogate marker of inflammation in CKD.[@R20] Our study showed that despite no correlation between total WBC and reduced kidney function, CKD was associated with higher neutrophil and lower lymphocyte counts; both of which are independently associated with the promotion of atherosclerosis[@R44] and poor cardiovascular outcomes.[@R46] N/L ratio, which combines the predictive power of both increased neutrophil count and decreased lymphocyte count,[@R47] was associated with reduced eGFR in our study, as also found in other studies.[@R23] Indeed previous studies, which included patients with CKD on haemodialysis[@R23] and predialysis,[@R49] showed that an increased N/L ratio was associated with known inflammatory markers such as tumour necrosis factor-α,[@R23] interleukin 6 and hsCRP levels.[@R49] These studies demonstrated that these well-established markers of inflammation were independent factors for predicting N/L ratio, thus presenting N/L ratio as an inflammatory biomarker for patients with CKD. Since full blood count analysis are done routinely, and a relatively affordable and easy measure to acquire, these findings are especially valuable taking into account the severely resource limited setting found in Africa and other low-income and middle-income countries.

Our study has a few limitations. This study was conducted in only one geographical area which may not adequately reflect all the mixed ancestry population groups in Sub-Saharan Africa. Furthermore, this was a community-based sample with high female to male participation, however the latter being a common trend in South African population studies. Our study also used a single serum creatinine measure to determine the grade of kidney function and did not include estimates of albuminuria. Albuminuria, in particular, is required for clinical and aetiological diagnosis of CKD, as this information is important particularly in the interpretation of eGFR greater that 60 mL/min/1.73 m^2^ where inaccuracies of the eGFR equations are greatest. It is however a common practice in community-based studies to diagnose CKD using a single measurement of serum creatinine. Furthermore, we did not investigate other haematinic deficiencies, such as vitamin B~12~ and iron deficiencies which, if present however, are less likely to affect haematological profile in a differential way in people with and without CKD. However, despite these limitations, we are not aware of other studies that have assessed the haematological profile of individuals with reduced kidney function in a population-based setting in Africa, even more specific, individuals of mixed-ancestry. Furthermore, we studied a community with a high burden of obesity, hypertension and diabetes, reflective of the current burden in Africa. This study provides much needed evidence for the association between the haematological profile and CKD as population-based data on the haematological profile of people with CKD in Africa are very limited.

In conclusion, the findings from our study are valuable as full blood count analyses are done routinely and are relatively affordable, taking into account the severely resource-limited setting found in Africa and other low-income and middle-income countries. Furthermore, though it still remains unclear whether the advocated kidney function estimators provide accurate estimates of CKD burden in African populations,[@R49] the correlation of these estimates, with deteriorating profile of blood cell counts, suggests that these advocated GFR estimates, particularly the CKD-EPI equation, to some extent, measure kidney function in African populations.
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